Granted Patent
B2
US 12,540,940 · App. 18/173,892 · Granted Feb 3, 2026
Biomarkers for the early detection of breast cancer
Inventors:
Joshua Labaer (Chandler, AZ); Karen Sue Anderson (Chestnut Hill, MA); Garrick Wallstrom (Mesa, AZ); Sahar Sibani (Revere, MA); Niroshan Ramachandran (San Marcos, CA)
Assignees:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE; ARIZONA BOARD OF REGENTS; DANA-FARBER CANCER INSTITUTE, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides reagents and methods for breast cancer detection.
Claims (8)
1 . A polynucleotide array comprising:
(a) a support; and
(b) at least 2 different isolated nucleic acids encoding polypeptides selected
from the group consisting of ATP6AP1 (SEQ ID NO: 14), PDCD6IP (SEQ ID NO: 22), DBT (SEQ ID NO: 26), CSNKIE (SEQ ID NO: 10), FRS3 (SEQ ID NO: 4), HOXD1 (SEQ ID NO: 8), SF3A1 (SEQ ID NO: 2), C15orf48 (SEQ ID NO: 36), MYOZ2 (SEQ ID NO: 34), BAT4 (SEQ ID NO: 6), BMX (SEQ ID NO: 46), RAB5A (SEQ ID NO: 24), UBAP1 (SEQ ID NO: 48), GPR157 (SEQ ID NO: 44), ZMYM6 (SEQ ID NO: 42), SLC33A1 (SEQ ID NO: 12), TRIM32 (SEQ ID NO: 38), ALG10 (SEQ ID NO: 28), TFCP2 (SEQ ID NO: 50), SERPINH1 (SEQ ID NO: 52), SELL (SEQ ID NO: 56), ZNF510 (SEQ ID NO: 54), or antigenic fragments thereof, attached to the support wherein the array comprise no more than 100 different isolated nucleic acids;
wherein the polynucleotide array is a Nucleic Acid Protein Programmable Array.
2 . The polynucleotide array of claim 1 , wherein at least 1 of the at least 2 different isolated nucleic acids encodes ATP6AP1 (SEQ ID NO: 14), or an antigenic fragment thereof.
3 . The polynucleotide array of claim 1 , wherein the array comprise no more than 50 different isolated nucleic acids.
4 . The polynucleotide array of claim 1 , wherein the array comprise no more than 25 different isolated nucleic acids.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 20, 2025
From: LABAER, JOSHUA; SIBANI, SAHAR; RAMACHANDRAN, NIROSHAN
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 072600/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 20, 2025
From: ANDERSON, KAREN
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 072600/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 20, 2025
From: WALLSTROM, GARRICK
To: ARIZONA BOARD OF REGENTS, A BODY CORPORATE ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
Reel/Frame 072600/0381 →
Continuity (5)
Continuation
13809695
Provisional Application
61373359
· Aug 13, 2010
References Cited (159)
US 7402403B1
· Robertson et al.
· 2008
[cited by applicant]
US 9141756B1
· Hillis et al.
· 2015
[cited by applicant]
US 9442111B2
· Lindsay et al.
· 2016
[cited by applicant]
US 9535070B2
· Saul et al.
· 2017
[cited by applicant]
US 9857374B2
· LaBear et al.
· 2018
[cited by applicant]
US 9938523B2
· LaBaer
· 2018
[cited by applicant]
US 20040048256A1
· Agee et al.
· 2004
[cited by applicant]
US 20090136917A1
· Szalay et al.
· 2009
[cited by applicant]
US 20100159469A1
· Harris et al.
· 2010
[cited by applicant]
US 20140162902A1
· LaBaer et al.
· 2014
[cited by applicant]
US 20140371091A1
· Wiktor et al.
· 2014
[cited by applicant]
US 20150362497A1
· Anderson et al.
· 2015
[cited by applicant]
US 20160195546A1
· LaBaer et al.
· 2016
[cited by applicant]
US 20170045515A1
· Anderson et al.
· 2017
[cited by applicant]
US 20170115299A1
· Saul et al.
· 2017
[cited by applicant]
US 20170176423A1
· Anderson et al.
· 2017
[cited by applicant]
US 20170363631A1
· LaBaer et al.
· 2017
[cited by applicant]
US 20180267029A1
· Wiktor et al.
· 2018
[cited by applicant]
US 20180320230A1
· LaBaer et al.
· 2018
[cited by applicant]
US 20190004051A1
· LaBaer et al.
· 2019
[cited by applicant]
US 20190162725A1
· Magee et al.
· 2019
[cited by applicant]
JP 6826870
· 2019
[cited by applicant]
WO 2002012067A2
· 2003
[cited by applicant]
WO 2003012067A2
· 2003
[cited by applicant]
WO 2003073911A2
· 2003
[cited by applicant]
WO 2005010180A1
· 2005
[cited by applicant]
WO 2005106044A1
· 2005
[cited by applicant]
WO 2007147265A1
· 2007
[cited by applicant]
WO 2008021290A2
· 2008
[cited by applicant]
WO 2008030845A2
· 2008
[cited by applicant]
WO 2008106660A1
· 2008
[cited by applicant]
WO 2009108917A2
· 2009
[cited by applicant]
WO 2010083252A2
· 2010
[cited by applicant]
WO 2012021887A2
· 2012
[cited by applicant]
WO 2013019680A1
· 2013
[cited by applicant]
WO 2013063126A2
· 2013
[cited by applicant]
WO 2013090364A1
· 2013
[cited by applicant]
WO 2014120902A1
· 2014
[cited by applicant]
WO 2014143954A2
· 2014
[cited by applicant]
WO 2014145458A1
· 2014
[cited by applicant]
WO 2015148202A1
· 2015
[cited by applicant]
WO 2015167678A1
· 2015
[cited by applicant]
WO 2015167678A8
· 2015
[cited by applicant]
WO 2015175755A1
· 2015
[cited by applicant]
WO 2016094558A1
· 2016
[cited by applicant]
WO 2016141044A1
· 2016
[cited by applicant]
WO 2017048709A1
· 2017
[cited by applicant]
WO 2017075141A1
· 2017
[cited by applicant]
WO 2017075141A8
· 2017
[cited by applicant]
WO 2017123648A1
· 2017
[cited by applicant]
WO 2017218677A2
· 2017
[cited by applicant]
WO 2018013531A1
· 2018
[cited by applicant]
WO 2018013531A8
· 2018
[cited by applicant]
WO 2019136169A1
· 2019
[cited by applicant]
WO 2019241361A1
· 2019
[cited by applicant]
Barderas et al., 2009. Setting-up an antibody nucleic-acid programmable protein array (NAPPA) antibody microarray platform. Proteomica: revista de la Sociedad Española de Proteomica, 3, p. 101. (Year: 2009).
[cited by examiner]
Diez et al., 2015. NAPPA as a real new method for protein microarray generation. Microarrays, 4(2), pp. 214-227. (Year: 2015).
[cited by examiner]
He et al., 2008. Printing protein arrays from DNA arrays. Nature methods, 5(2), pp. 175-177. (Year: 2008).
[cited by examiner]
Link, A.J. and LaBaer, J., 2008. Construction of nucleic acid programmable protein arrays (NAPPA) 4: DNA biotinylation, precipitation, and arraying of samples. Cold Spring Harbor Protocols, 2008(11) 3, 1-5. (Year: 2008).
[cited by examiner]
Anderson, Karen S., et al., “Protein Microarray Signature of Autoantibody Biomarkers for Early Detection of Breast Cancer,” J. Proteome Res., Jan. 2011, pp. 85-96, vol. 10, No. 1.
[cited by applicant]
Anderson, Karen S., et al., In “Using custom protein microarrays to identify autoantibody biomarkers for the early detection of breast cancer,” San Antonio Breast Cancer Symposium, San Antonio, TX, 2008. (abstract).
[cited by applicant]
Anderson, Karen S., et al., “Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.” J. Proteome Res., Apr. 2008, pp. 1490-1499, vol. 7, No. 4.
[cited by applicant]
Anderson, Karen S., et al., “The sentinel within: exploiting the immune system for cancer biomarkers,” J. Proteome Res., Jul.-Aug. 2005, pp. 1123-1133, vol. 4, No. 4.
[cited by applicant]
Anderson, N. Leigh, et al., “The human plasma proteome: history, character, and diagnostic prospects,” Mol. Cell. Proteomics, Nov. 2002, pp. 845-867, vol. 1, No. 11.
[cited by applicant]
Baugher, Paige J., et al., “Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells,” Breast Cancer Res., 2005, pp. R965-74, vol. 7, No. 6.
[cited by applicant]
Breiman, Leo, “Random Forests.” Mach. Learn., 2001, pp. 5-32, vol. 45.
[cited by applicant]
Bouwman, Kerri, et al., “Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity,” Proteomics, Nov. 2003, pp. 2200-2207, vol. 3, No. 11.
[cited by applicant]
Chapman, C., et al., “Autoantibodies in breast cancer: their use as an aid to early diagnosis,” Ann. Oncol., May 2007, pp. 868-873, vol. 18, No. 5.
[cited by applicant]
Chatterjee, Madhumita, et al., “Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays,” Cancer Res., Jan. 2006, pp. 1181-1190, vol. 66, No. 2.
[cited by applicant]
Chen, Kai-Yun, et al., “The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDAMB-468 breast cancer cells,” Oncogene, 2004, pp. 1854-1862, vol. 23, No. 10.
[cited by applicant]
Chen, Yupeng, et al., “The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer,” J. Biol. Chem., Jun. 2008, pp. 17969-17978, vol. 283, No. 26.
[cited by applicant]
Chen, Guoan, et al., “Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma,” Cancer Res., Apr. 2007, pp. 3461-3467, vol. 67, No. 7.
[cited by applicant]
Csepregi, Antal, et al., “Characterization of a lipoyl domain-independent B-cell autoepitope on the human branched-chain acyltransferase in primary biliary cirrhosis and overlap syndrome with autoimmune hepatitis,” Clin…
[cited by applicant]
Desmetz, Caroline, et al., “Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women,” Clin. Cancer Res., Jul. 2009, pp. 4733-4741, vol. 15, …
[cited by applicant]
Edwards, Brenda K., et al., “Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment,” J. Natl. Cancer Inst., Oct. 2005, pp. 1407-1427, vol. 97, No. 19.
[cited by applicant]
Efron, B., “Bootstrap Methods: Another Look at the Jackknife,” Ann. Stat., 1979, pp. 1-26, vol. 7, No. 1.
[cited by applicant]
Esserman, M.D., Laura, et al., “Rethinking screening for breast cancer and prostate cancer,” J. Am. Med. Assoc., Oct. 2009, pp. 1685-1692, vol. 302, No. 15.
[cited by applicant]
Esserman, M.D., Laura, et al., “A role for biomarkers in the screening and diagnosis of breast cancer in younger women,” Expert Rev. Mol. Diagn., Sep. 2007, pp. 533-544, vol. 7, No. 5.
[cited by applicant]
Forti, Stefania, et al., “Identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum,” Breast Cancer Res. Treat., Jun. 2002, pp. 245-256, vol. 73,…
[cited by applicant]
Fossa ; Alexander, et al., “Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display,” Cancer Immunol. Immunother., May 2004, pp. 431-438, vol. 53, No. 5.
[cited by applicant]
Gnjatic, Sacha, et al., “Seromic profiling of ovarian and pancreatic cancer,” Proc. Natl. Acad. Sci., Mar. 2010, pp. 5088-5093, vol. 107, No. 11.
[cited by applicant]
Grzmil, Michal, et al., “An oncogenic role of eIF3e/INT6 in human breast cancer,” Oncogene, Jul. 2010, pp. 4080-4089, vol. 29, No. 28.
[cited by applicant]
Gu{umlaut over ( )}re, Ali O., et al., “Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer,” Proc. Natl. Acad. Sci. U.S.A., Apr. 2000, pp. 4198-4203, v…
[cited by applicant]
Gu{umlaut over ( )}re, Ali O., et al., “Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene loc US on chromosome 3p21.3,” Cancer Res., Mar. 1…
[cited by applicant]
Harris, Lyndsay, et al., “American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer,” J. Clin. Oncol., Nov. 2007, pp. 5287-5312, vol. 25, No. 33.
[cited by applicant]
Hartmann, Lynn C., et al., “Benign breast disease and the risk of breast cancer,” N. Engl. J. Med., Jul. 2005, pp. 229-237, vol. 353, No. 3.
[cited by applicant]
Hattori, Takako, et al., “Rheumatoid arthritis-related antigen 47 kDa (RAA47) is a product of colligin-2 and acts as a human HSP47,” J. Bone Miner. Metab., 2000, pp. 328-334, vol. 18, No. 6.
[cited by applicant]
Hodi, F. Stephen, et al., “ATP6S1 elicits potent humoral responses associated with immunemediated tumor destruction,” Proc. Natl. Acad. Sci., May 2002, pp. 6919-6924, vol. 99, No. 10.
[cited by applicant]
Hudson, Michael E., et al., “Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays,” Proc. Natl. Acad. Sci. U.S.A., Oct. 2007, pp. 17494-17499, vol. 104, No. 44.
[cited by applicant]
Huttenhower, Curtis, et al., “Exploring the human genome with functional maps,” Genome Res., Jun. 2009, pp. 1093-1106, vol. 19, No. 6.
[cited by applicant]
Iejima, Daisuke, et al., “FRS2beta, a potential prognostic gene for non-small cell lung cancer, encodes a feedback inhibitor of EGF receptor family members by ERK binding,” Oncogene, May 2010, pp. 3087-3099, vol. 29, No…
[cited by applicant]
Ja{umlaut over ( )}ger, Dirk, et al., “Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library,” Cancer Res., Mar. 2001, pp. 2055-2061, vol.…
[cited by applicant]
Ja{umlaut over ( )}ger, Dirk, et al., Antibodies and vaccines—hope or illusion, Breast, Dec. 2005, pp. 631-635, vol. 14, No. 6.
[cited by applicant]
Ja{umlaut over ( )}ger, Dirk, et al., Identification of tumorrestricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum, Ca…
[cited by applicant]
Joos, Thomas O., et al., “Miniaturised multiplexed immunoassays,” Curr. Opin. Chem. Biol., Feb. 2002, pp. 76-80, vol. 6, No. 1.
[cited by applicant]
Kano, Satoshi, et al., “Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2,” Cancer Res., Jul. 2008, pp. 5572-5580, vol. 68, No. 14.
[cited by applicant]
Koziol, James A., et al., “Recursive partitioning as an approach to selection of immune markers for tumor diagnosis,” Clin. Cancer Res., Nov. 2003, pp. 5120-5126, vol. 9, No. 14.
[cited by applicant]
Kwok, Sukyee, et al., “Transforming growth factorbeta1 regulation of ATF-3 and identification of ATF-3 target genes in breast cancer cells,” J. Cell. Biochem., Oct. 2009, pp. 408-414, vol. 108, No. 2.
[cited by applicant]
Lichtenfels, Rudolf, et al., “Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses,” Biochim. Biophys. Acta., Mar. 2003, pp. 21-31, vol. 1646, Nos. 1-2.
[cited by applicant]
Macbeath, Gavin, et al., “Printing proteins as microarrays for high-throughput function determination,” Science, Sep. 2000, pp. 1760-1763, vol. 289, No. 5485.
[cited by applicant]
Mahul-Mellier, Anne-Laure, et al., “Alix and ALG-2 are involved in tumor necrosis factor receptor 1-induced cell death,” J. Biol. Chem., Dec. 2008, pp. 34954-34965, vol. 283, No. 50.
[cited by applicant]
Marchese, Rocio D., et al., “Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human ser…
[cited by applicant]
Mcclish, Donna K., “Analyzing a portion of the ROC curve,” Med. Decis. Making, Jul.-Sep. 1989, pp. 190-195, vol. 9, No. 3.
[cited by applicant]
Minenkova, Olga, et al., “Identification of tumorassociated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients,” Int. J. Cancer, Sep. 2003, pp. 534-544, vol. 106, No. 4.
[cited by applicant]
Mira, Jean-Paul, et al., “Endogenous, hyperactive Rac3 controls proliferation of breast cancer cells by a p21-activated kinase-dependent pathway,” Proc. Natl. Acad. Sci., Jan. 2000, pp. 185-189, vol. 97, No. 1.
[cited by applicant]
Nese, M.D., Nalan, et al., “Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fasci…
[cited by applicant]
Palijan, Ana, et al., “Ligand-dependent corepressor LCOR is an attenuator of progesterone-regulated gene expression,” J. Biol. Chem., Oct. 2009, pp. 30275-30287, vol. 284, No. 44.
[cited by applicant]
Parkin, D. Max, et al., “Global cancer statistics, 2002,” CA Cancer J. Clin., Mar.-Apr. 2005, pp. 74-108, vol. 55, No. 2.
[cited by applicant]
Petricoin, Emmanuel, et al., “Clinical proteomics: revolutionizing disease detection and patient tailoring therapy,” J. Proteome Res., Mar.-Apr. 2004, pp. 209-217, vol. 3, No. 2.
[cited by applicant]
Qian, Jun, et al., “[Identification of digital differential expression patterns of a novel human gene (UBAP1) by an expressed sequence tag strategy],” [Ai zheng = Chinese Journal of Cancer], 2002, pp. 225-228, vol. 21, …
[cited by applicant]
Qiu, Ji, et al., “Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens,” J. Proteome Res., Mar.-Apr. 2004, pp. 261-267, vol. 3, No. 2.
[cited by applicant]
Ramachandran, Niroshan, et al., “Self-assembling protein microarrays,” Science, Jul. 2004, pp. 86-90, vol. 305, No. 5680.
[cited by applicant]
Ramachandran, Niroshan, et al., “Next-generation highdensity self-assembling functional protein arrays,” Nat. Methods, Jun. 2008, pp. 535-538, vol. 5, No. 6.
[cited by applicant]
Ramachandran, Niroshan, et al., Tracking humoral responses using self assembling protein microarrays, Proteomics Clin. Appl., Oct. 2008, pp. 1518-1527, vol. 2, Nos. 10-11.
[cited by applicant]
Richardson, Andrea L., et al., “X chromosomal abnormalities in basal-like human breast cancer,” Cancer Cell, Feb. 2006, pp. 121-132, vol. 9, No. 2.
[cited by applicant]
Robinson, William H., et al., “Autoantigen microarrays for multiplex characterization of autoantibody responses,” Nat. Med., Mar. 2002, pp. 295-301, vol. 8, No. 3.
[cited by applicant]
Schmoor, C., et al., “Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF.” Eur. J. Cancer, Jun. 2001, pp. 1123-1131, vol. 37, No. 9.
[cited by applicant]
Sioud, Mouldy, et al., “Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries,” Eur. J. Immunol., Mar. 2001, pp. 716-725, vol. 31, No. 3.
[cited by applicant]
Stockert, Elisabeth, et al., “A survey of the humoral immune response of cancer patients to a panel of human tumor antigens,” J. Exp. Med., Apr. 1998, pp. 1349-1354, vol. 187, No. 8.
[cited by applicant]
Stoll, Dieter, et al., “Protein microarray technology,” Front. Biosci., Jan. 2002, pp. c13-c32, vol. 7.
[cited by applicant]
Storey, John D., “A direct approach to false discovery rates,” J. R. Stat. Soc. B, 2002, pp. 479-498, vol. 64, Pt. 3.
[cited by applicant]
Tamimi, Rulla M., “Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women,” J. Natl. Cancer Inst., Aug. 2007, pp. 1178-1187, vol. 99, No. 15.
[cited by applicant]
Tamimi, Rulla M., “Endogenous sex hormone levels and mammographic density among postmenopausal women,” Cancer Epidemiol. Biomarkers Prev., Nov. 2005, pp. 2641-2647, vol. 14, No. 11 Pt. 1.
[cited by applicant]
Templin, Markus F., et al., “Protein microarrays: promising tools for proteomic research,” Proteomics, Nov. 2003, pp. 2155-2166, vol. 3, No. 11.
[cited by applicant]
Torres, Vicente A., et al., “Rab5 mediates caspase-8-promoted cell motility and metastasis,” Mol. Biol. Cell, Jan. 2010, pp. 369-376, vol. 21, No. 2.
[cited by applicant]
Tozlu, Sengu{umlaut over ( )}l, et al., “Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach,” En…
[cited by applicant]
Wandall, Hans H., et al., “Cancer biomarkers defined by autoantibody signatures to aberrant Oglycopeptide epitopes,” Cancer Res., Feb. 2010, pp. 1306-1313, vol. 70, No. 4.
[cited by applicant]
Wang, Cheng-Chi, et al., “Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer,” Proc. Natl. Acad. Sci., Aug. 2008, pp. 11661-11666, vol. 105, No. 33.
[cited by applicant]
Wang, Xiaoju, et al., “Autoantibody signatures in prostate cancer,” N. Engl. J. Med., Sep. 2005, pp. 1224-1235, vol. 353, No. 12.
[cited by applicant]
Witt, Abigail E., et al., “Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer,” J. Proteome Res., Mar. 2006, pp. 599-610, vol. 5, No. 3.
[cited by applicant]
Wong, Jessica, et al., “Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays,” J. Immunol. Methods, Oct. 2009, pp. 171-182, vol. 350, Nos. 1-2.
[cited by applicant]
Wulfkuhle, Julia D., et al., “New approaches to proteomic analysis of breast cancer,” Proteomics, Oct. 2001, pp. 1205-1215, vol. 1, No. 10.
[cited by applicant]
Zhao, Hongjuan, “Different gene expression patterns in invasive lobular and ductal carcinomas of the breast,” Mol. Biol. Cell, Jun. 2004, pp. 2523-2536, vol. 15, No. 6.
[cited by applicant]
Zhou, Jin, et al., “A novel gene, NMES1, downregulated in human esophageal squamous cell carcinoma,” Int. J. Cancer, 2002, 101 (4), 311-6.
[cited by applicant]
Zhu, Henh, et al., “Global analysis of protein activities using proteome chips,” Science, Sep. 2001, pp. 2101-2105, vol. 293, No. 5537.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2011/047741 mailed Mar. 23, 2012 (19 pages).
[cited by applicant]
International Preliminary Report on Patentability for PCT/US2011/047741 issued Feb. 19, 2013 (11 pages).
[cited by applicant]
Davis, et al., Amplification Patterns of three genomic regions predict distant recurrence in breast carcinoma, Journal of Molecular Diagnostics, 9(3): 327-336. Jul. 2007.
[cited by applicant]
Pan, et al., “Involvement of the Conserved adaptor protein alix in actin cytoskeleton assembly,” Journal of Biological Chemistry, 281(45): 34640-34650, Nov. 2006.
[cited by applicant]
Zhao, et al., “different gene expression patterns in invasive lobular and ductal carcinomas of the breast,” Molecular Biology of the Cell, 15(6): 2523-2536, Jan. 2004.
[cited by applicant]
Thatcher, et al., “Regulation of zebrafish fin regeneration by microRNAs,” Proceedings of the National Academy of Sciences, 105(47): 18384-18389, Nov. 2008.
[cited by applicant]
Yamashita, et al., “Suppression of invasive characteristics by antisense introduction of overexpressed HOX genes in ovarian cancer cells,” International Journal of Oncology, 28: 931, Apr. 2006.
[cited by applicant]
Yoo, et al., “Transcriptional factor Late SV40 Factor (LSF) functions as an oncogene in hepatocellular carcinoma,” PNAS, 107(18): 8357-8362, Apr. 2010.
[cited by applicant]
European Search Report for EP3054299, mailed Oct. 16, 2016.
[cited by applicant]
Madrid, et al. “Autoantibodies in breast cancer identify proteins involved in self-renewal and epigenetic chromatin remodeling” The Open Biomarkers Journal, 3: 13-20 (2010).
[cited by applicant]
Tan, et al., “Serum autoantibodies as biomarkers for early cancer detection,” FEBS Journal, 276: 6880-6900 (2009).
[cited by applicant]
Cameron et al., (Plos ONE. Jan. 2009,4(1 ):e403(8 pages) doi:1 0.1371/journal.pone.0004303).
[cited by applicant]
U.S. Appl. No. 16/097,791, LaBaer et al., filed Oct. 30, 2018.
[cited by applicant]
U.S. Appl. No. 16/743,906, LaBaer et al., filed Jan. 15, 2020.
[cited by applicant]
U.S. Appl. No. 16/791,640, LaBaer et al., filed Feb. 14, 2020.
[cited by applicant]
Marella NV, Malyavantham KS, Wang J, Matsui S, Liang P, Berezney R. Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines. Cancer Res. Jul. 15, 2009;69(14):5946-53. doi:…
[cited by applicant]